^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:nintedanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

    Excerpt:
    ...- Patients with EGFR mutations or ALK rearrangements must have disease progression on appropriate FDA-approved therapy for these genomic aberrations prior to enrollment....
    Trial ID:
    NCT02299141
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

    Excerpt:
    ...Positive EGFR mutations are diagenesis....
    Trial ID:
    NCT06071013
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Transl Oncol
    Title:

    Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

    Published date:
    07/22/2021
    Excerpt:
    ...analyzed 19 patients with advanced EGFR-mutant NSCLC who had progressed to EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy receiving docetaxel and nintedanib....Our data indicate that the combination of docetaxel and nintedanib can be considered to be an effective treatment for EGFR TKI-resistant EGFR-mutant NSCLC.
    Secondary therapy:
    docetaxel
    DOI:
    10.1007/s12094-021-02661-2